Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT04474899
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT04474899
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia
- Registry status
- Unknown status
Technical summary
Registry record NCT04474899. Randomized; quadruple masking; primary purpose treatment. Start 2015-06-24 (actual); primary completion 2024-02-24 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension
- Acronym
- OHT
- Condition
- Obesity
- Condition
- Hypertension
- Intervention (Drug)
- Moxonidine 0.4 MG
- Intervention (Drug)
- Amlodipine 5mg
- Lead sponsor
- Royal Perth Hospital
- Collaborator
- The University of Western Australia
Record details
- Record id
cardio:ct-nct04474899- Content hash
61d27de21d28a7dda2184df9ed7c3aa30722b3ea7434bde4f6112ba7da7a81d8